Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
2021 · Proceedings of the National Academy of Sciences · 119 citations
https://doi.org/10.1073/pnas.2026849118
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
893
Citations
2
h-index
2
i10-index
Rosalynd Upton is an academic researcher from California Institute for Regenerative Medicine. The author has contributed to research in topics: Phagocytosis and Immune Regulation & Nanoparticle-Based Drug Delivery & Biofuel production and bioconversion. The author has an h-index of 2, co-authored 4 publications.
Click to start Chat